Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
作者信息
Ehmsen Sidse, Asmussen Anders, Jeppesen Stefan S, Nilsson Anna Christine, Østerlev Sabina, Vestergaard Hanne, Justesen Ulrik S, Johansen Isik S, Frederiksen Henrik, Ditzel Henrik J
机构信息
Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark.
Department of Hematology, Odense University Hospital, Odense, Denmark.
出版信息
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
Abstract
摘要
相似文献
1
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
2
A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.一剂自我转录和复制的基于 RNA 的 SARS-CoV-2 疫苗可在小鼠中产生保护性适应性免疫。
Mol Ther. 2021 Jun 2;29(6):1970-1983. doi: 10.1016/j.ymthe.2021.04.001. Epub 2021 Apr 5.
3
Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？
Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.
4
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.COVID-19 疫苗 mRNA-1273 在小鼠中引发了保护性免疫谱，而在 SARS-CoV-2 挑战时，这种免疫谱与疫苗增强疾病无关。
Immunity. 2021 Aug 10;54(8):1869-1882.e6. doi: 10.1016/j.immuni.2021.06.018. Epub 2021 Jul 2.
5
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.单剂 mRNA 疫苗为 hACE2 转基因小鼠提供了针对 SARS-CoV-2 的长期保护。
Nat Commun. 2021 Feb 3;12(1):776. doi: 10.1038/s41467-021-21037-2.
6
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.癌症患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2 mRNA疫苗延迟第二剂的体液免疫和细胞免疫
Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.
7
SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.灭活新冠疫苗接种者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）结构蛋白的特异性T细胞免疫
Cell Mol Immunol. 2021 Aug;18(8):2040-2041. doi: 10.1038/s41423-021-00730-8. Epub 2021 Jul 15.
8
SARS-CoV-2 evolution and vaccines: cause for concern?严重急性呼吸综合征冠状病毒2的进化与疫苗：令人担忧吗？
Lancet Respir Med. 2021 Apr;9(4):333-335. doi: 10.1016/S2213-2600(21)00075-8. Epub 2021 Jan 29.
9
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.异源疫苗接种方案，使用自我扩增 RNA 和腺病毒 COVID 疫苗，可在小鼠中诱导强烈的免疫反应。
Nat Commun. 2021 May 17;12(1):2893. doi: 10.1038/s41467-021-23173-1.
10
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
引用本文的文献
1
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.癌症患者多次接种新冠病毒疫苗加强针后的循环严重急性呼吸综合征冠状病毒2刺突蛋白IgG抗体反应
Front Immunol. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473. eCollection 2025.
2
SARS-CoV-2 vaccination unmasks distinct immune dysfunctions across lymphoma subtypes and therapies.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗接种揭示了不同淋巴瘤亚型和治疗方法中独特的免疫功能障碍。
Res Sq. 2025 Jul 4:rs.3.rs-7016519. doi: 10.21203/rs.3.rs-7016519/v1.
3
Patterns of SARS-CoV-2-specific humoral and cellular immune response in actively treated patients with solid cancer following prime BNT162b2 COVID-19 vaccination: results from phase IV CoVigi trial.BNT162b2新冠疫苗初免后接受积极治疗的实体癌患者中SARS-CoV-2特异性体液和细胞免疫反应模式：IV期CoVigi试验结果
Ther Adv Med Oncol. 2025 May 17;17:17588359251316224. doi: 10.1177/17588359251316224. eCollection 2025.
4
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.多发性骨髓瘤患者的SARS-CoV-2免疫反应及来那度胺维持治疗
Front Immunol. 2024 Dec 18;15:1510942. doi: 10.3389/fimmu.2024.1510942. eCollection 2024.
5
COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19.COVID-19 与癌症护理：COVID-19 时代癌症患者护理的综述与实用指南。
Curr Oncol. 2024 Sep 10;31(9):5330-5343. doi: 10.3390/curroncol31090393.
6
Low booster uptake in cancer patients despite health benefits.尽管有健康益处，但癌症患者的加强针接种率较低。
iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20.
7
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.mRNA-1273 疫苗接种可诱导接受免疫治疗和/或化疗的实体瘤患者产生多功能记忆 CD4 和 CD8 T 细胞应答。
Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024.
8
Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients.血浆细胞外囊泡微小RNA作为癌症患者COVID-19疫苗免疫反应的潜在生物标志物
Vaccines (Basel). 2024 Jul 28;12(8):848. doi: 10.3390/vaccines12080848.
9
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.COVID-19 疫苗在实体瘤患者中的免疫应答：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357424. doi: 10.1080/21645515.2024.2357424. Epub 2024 May 24.
10
Immunogenicity Parameters of Cancer Patients Receiving the mRNA Vaccine BNT162b2 While Obtaining Radiotherapy: A Longitudinal Cohort Evaluation.接受mRNA疫苗BNT162b2同时进行放疗的癌症患者的免疫原性参数：一项纵向队列评估
Vaccines (Basel). 2024 Mar 6;12(3):275. doi: 10.3390/vaccines12030275.
本文引用的文献
1
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution.癌症患者对 COVID-19 疫苗的免疫反应：有希望的结果和谨慎的提示。
Cancer Cell. 2021 Aug 9;39(8):1045-1047. doi: 10.1016/j.ccell.2021.07.001. Epub 2021 Jul 3.
2
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
3
WHO International Standard for anti-SARS-CoV-2 immunoglobulin.世界卫生组织抗2019冠状病毒病免疫球蛋白国际标准品。
Lancet. 2021 Apr 10;397(10282):1347-1348. doi: 10.1016/S0140-6736(21)00527-4. Epub 2021 Mar 23.
4
Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study.实体瘤癌症患者感染 SARS-CoV-2 的严重程度和 1 个月预后：一项丹麦全国队列研究。
Acta Oncol. 2021 Jul;60(7):859-865. doi: 10.1080/0284186X.2021.1889659. Epub 2021 Mar 1.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
6
COVID-19 and Cancer: Current Challenges and Perspectives.新型冠状病毒肺炎与癌症：当前挑战与展望。
Cancer Cell. 2020 Nov 9;38(5):629-646. doi: 10.1016/j.ccell.2020.09.018. Epub 2020 Oct 1.
7
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.一项在成人中开展的 COVID-19 RNA 疫苗 BNT162b1 的 I/II 期研究。
Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12.
8
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.原发性乳腺癌化疗后的淋巴细胞耗竭与再增殖
Breast Cancer Res. 2016 Jan 26;18(1):10. doi: 10.1186/s13058-015-0669-x.
9
Trends in cancer in the elderly population in Denmark, 1980-2012.1980 - 2012年丹麦老年人口的癌症趋势
Acta Oncol. 2016;55 Suppl 1:1-6. doi: 10.3109/0284186X.2015.1114678. Epub 2016 Jan 19.
Zotero 插件